DRESS Syndrome and Daclizumab Failure—Were Potentially Dangerous Signs Missed in Clinical Trials?
The US Food and Drug Administration (FDA) approved Zinbryta, an interleukin-2 receptor blocking antibody (daclizumab; Biogen and AbbVie) for the treatment of adults with relapsing forms of multiple sclerosis (MS) in May, 2016. It was also approved by the European Union in July, 2016. Zinbryta is a l...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2018-06-01
|
| Series: | Drug Target Insights |
| Online Access: | https://doi.org/10.1177/1177392818785136 |